Prostate News Archive
26-Dec-2008
Gay and bisexual African-American men have the lowest use of prostate testing (PhysOrg)
Gay and bisexual black men are less likely to be tested for prostate cancer than men of any other racial and ethnic backgrounds regardless of their sexual orientation, according to a recent study by a researcher at Charles Drew University of Medicine and Science. Men who live alone fall short on prostate screening (Reuters via Yahoo! News)
Men at higher-than-average risk of prostate cancer are more likely to seek regular screening if they are married or live with a significant other, a new study finds. FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer (ITNews)
PARSIPPANY, New Jersey, December 24 /PRNewswire/ -- - New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. St. James offers new treatment for prostate cancer (The Montana Standard)
A new procedure to combat prostate cancer is being performed at St. James Healthcare in Butte. FDA Approves Ferring Pharmaceuticals' Degarelix (Generic Name) for Treatment of Advanced Prostate Cancer (PR Newswire via Yahoo! Finance)
Releasing Hormone Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth.
Back to Prostate News Archive
